Unchecked |
Ki |
= |
4300.0 |
nM |
Inhibition of HCV NS5B RNA polymerase assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
Unchecked |
Ki |
= |
2500.0 |
nM |
Inhibition of HCV NS5B RNA polymerase S282T mutant assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
Unchecked |
Ki/Km |
= |
0.31 |
|
Ratio of Ki to Km for HCV NS5B RNA polymerase |
CHEMBL1142170 |
Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Ki/Km |
= |
0.93 |
|
Ratio of Ki to Km for HCV NS5B RNA polymerase S282T mutant |
CHEMBL1142170 |
Unchecked |
Ratio |
= |
3.0 |
|
Ratio of Ki/Km of HCV NS5B RNA polymerase S282T mutant to Ki/Km of HCV NS5B RNA polymerase |
CHEMBL1142170 |
Unchecked |
Km |
= |
13700.0 |
nM |
Inhibition of HCV NS5B RNA polymerase assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
Unchecked |
Km |
= |
2700.0 |
nM |
Inhibition of HCV NS5B RNA polymerase S282T mutant assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
Hepatitis C virus |
IC50 |
= |
130.0 |
nM |
Inhibition of RNA synthesis activity of HSV 1b Con1 NS5B polymerase |
CHEMBL1156500 |
Hepatitis C virus |
IC50 |
|
|
|
Antiviral activity against HCV 1b Con1 in 2209-23 cells after 72 hrs by luciferase based replicon assay |
CHEMBL1156500 |
Hepatitis C virus |
Ki |
= |
23.0 |
nM |
Inhibition of RNA synthesis activity of HSV 1b Con1 NS5B polymerase |
CHEMBL1156500 |
Hepatitis C virus |
IC50 |
= |
340.0 |
nM |
Inhibition of RNA synthesis activity of HSV 1b Con1 replicase |
CHEMBL1156500 |
Hepatocyte |
T1/2 |
= |
4.7 |
hr |
Drug uptake in human hepatocyte assessed as time needed for triphosphate to be reduced to half of maximum level |
CHEMBL1156500 |
Unchecked |
Ki |
= |
59.0 |
nM |
Inhibition of wild type HCV NS5B polymerase assessed as incorporation of [alpha32P]UTP into newly synthesized RNA by liquid scintillation counting |
CHEMBL1152990 |
Unchecked |
Km |
= |
74.0 |
nM |
Activity of wild type HCV NS5B polymerase |
CHEMBL1152990 |
Unchecked |
Ki/Km |
= |
0.8 |
|
Ratio of Ki to Km for wild type HCV NS5B polymerase |
CHEMBL1152990 |
Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Ki |
= |
310.0 |
nM |
Inhibition of HCV NS5B polymerase S282T mutant assessed as incorporation of [alpha32P]UTP into newly synthesized RNA by liquid scintillation counting |
CHEMBL1152990 |
Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Km |
= |
52.0 |
nM |
Activity of HCV NS5B polymerase S282T mutant |
CHEMBL1152990 |
Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Ki/Km |
= |
6.0 |
|
Ratio of Ki to Km for HCV NS5B polymerase S282T mutant |
CHEMBL1152990 |
Unchecked |
Ratio |
= |
7.5 |
|
Fold resistance, ratio of Ki/Km for HCV NS5B polymerase S282T mutant to Ki/Km for wild type HCV NS5B polymerase |
CHEMBL1152990 |
Unchecked |
IC50 |
= |
5370.0 |
nM |
Inhibition of HCV NS5B polymerase after 30 mins |
CHEMBL1208712 |
Unchecked |
Ki |
= |
59.0 |
nM |
Inhibition of HCV NS5B polymerase after 30 mins |
CHEMBL1208712 |
ADMET |
T1/2 |
= |
4.7 |
hr |
Half life in primary human hepatocytes treated with PSI-6130 at 2 uM by HPLC method |
CHEMBL4011639 |
Unchecked |
IC50 |
= |
1600.0 |
nM |
Inhibition of DENV RNA-dependent RNA polymerase activity |
CHEMBL5150000 |
Unchecked |
Inhibition |
= |
85.0 |
% |
Inhibition of DENV RNA-dependent RNA polymerase relative to control |
CHEMBL5150000 |
NS5 |
Inhibition |
= |
67.4 |
% |
Inhibition of Zika virus RNA-dependent RNA polymerase relative to control |
CHEMBL5150000 |